Caribou Biosciences (CRBU) Preferred Stock Liabilities (2020)

Caribou Biosciences (CRBU) reported Preferred Stock Liabilities of $41.3 million for Q4 2020.

Caribou Biosciences (CRBU) Preferred Stock Liabilities (2020) Analysis & Trends

Caribou Biosciences (CRBU) has 1 years of Preferred Stock Liabilities data on file, last reported at $41.3 million in Q4 2020.

Preferred Stock Liabilities for Q4 2020 came in at $41.3 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was $41.3 million (changed N/A YoY), and the FY2020 annual result was $41.3 million, changed N/A from the prior year.
Preferred Stock Liabilities steadied at $41.3 million in Q4 2020 per CRBU's latest filing.
Over five years, Preferred Stock Liabilities peaked at $41.3 million in Q4 2020 and troughed at $41.3 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Caribou Biosciences	156.73 Mn	39.11 Mn	-	-

Download Data

Date	Value
Dec 31, 2020	41.32 Mn